A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Neuroimaging Findings in Patients with AIDS
Clin Inf Dis 22:906-919, Walot,I.,et al, 1996
PET:Its Clinical Role in Neurology
JNNP 54:1-5, Brooks,D.J., 1991
Positron Emission Tomography-A New Approach to Brain Chemistry
JAMA 260:2704-2710, Jacobson,H.G., 1988
Positron Computed Tomography for Studies of Myocardial & Cerebral Function
Ann Int Med 98:339-359, Phelps,M.E.,et al, 1983
FDG-PET/CT of Giant Cell Arteritis with Normal Inflammatory Markers
Ann Neurol 92:337-339, Koizumi, N.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data
AJNR 41:980-986, Reith, F.,et al, 2020
Links in the Chain of Chronic Traumatic Encephalopathy
NEJM 380:1771-1772, Ropper, A.H., 2019
Florbetapir Imaging in Cerebral Amyloid Angiopathy-Related Hemorrhages
Neurol 91:574-577, Charidimou, A.,et al, 2018
Autopsy Validation of ���I-FP-CIT Dopaminergic Neuroimaging for the Diagnosis of DLB
Neurol 88:276-283, Thomas, A.J.,et al, 2017
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
Cortical and Cerebellar Hypometabolism After Bilateral Antero-Inferior Cerebellar Artery Infarct
Neurol 78:69-70, Ayrignac, X.,et al, 2012
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Predicting sites of New Hemorrhage with Amyloid Imaging in Cerebral Amyloid Angiopathy
Neurol 79:320-326, Gurol, M.E.,et al, 2012
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Presentation, Diagnosis, Pathophysiology, and Treatment of the Neurological Features of Sturge-Weber Syndrome
The Neurologist 17:179-184, Comi, A.M., 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Pediatric Moyamoya Disease: An Analysis of 410 Consecutive Cases
Ann Neurol 68:92-101, Kim,S.-K., et al, 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Positron Emission Tomography in Diagnosis of Visual Variant Alzheimer Disease
J Neuro-Ophthalmol 29:149-150, Finelli,P.F., 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Assessment of �-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography with Carbon 11-Labeled Pittsburgh Compound B
Arch Neurol 65:1304-1309,1281, Leinonen,V.,et al, 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
Episodic Neurologic Dysfunction with Migraine and Reversible Imaging Findings After RadiationRRH
Neurol 67:676-678, Pruitt,A.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
The Woman Who Needed a Pet
Surv Ophthalmol 51:592-595, Atchison,M.,et al, 2006
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Best Measure of Ischemic Penumbra: Positron Emission Tomography
Stroke 34:2534-2535, Heiss,W.-D., 2003
The Topography of Metabolic Deficits in Posterior Cortical Atrophy (the Visual Variant of Alzheimers Disease) with FDG-PET
JNNP 74:1521-1529, Nestor,P.J.,et al, 2003
Effect of Donepezil on Brain Acetylcholineserase Activity in Patients with AD Measured by PET
Neurol 56:408-410, Shinotoh,H.,et al, 2001
The Effect of Brain Atrophy on Cerebral Hypometabolism in the Visual Variant of Alzheimer Disease
Arch Neurol 58:480-486, Bokde,A.L.W.,et al, 2001
Transplantation of Cultured Human Neuronal Cells for Patients With Stroke
Neurol 55:565-569, 467, Kondziolka,D. et al, 2000
Ischemic Core and Penumbra in Human Stroke
Stroke 30:93-99, Kaufmann,A.M.,et al, 1999
Permanent Cortical Damage Detected by Flumazenil Positron Emission Tomography in Acute Stroke
Stroke 29:454-461, Heiss,W.,et al, 1998
Measurement of Acetylcholinesterase by PET in the Brains of Healthy Controls & Pts with Alzheimer's Disease
Lancet 349:1805-1809, Iyo,M.,et al, 1997
Clinical, Neuroimaging, and Pathologic Features of Progressive Nonfluent Aphasia
Ann Neurol 39:166-173, Turner,R.S.,et al, 1996